Home > Insider Trading > Filing (0001104659-13-041509)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1463729	Receptos Inc.	RCPT	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1552293	Edward S. Torres	10835 Road To The Cure, Suite 205 San Diego CA 92121		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2013-05-14	1,152,039	$5.25	1,266,324	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2013-05-14	672,029	$7.73	1,938,353	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2013-05-14	142,857	$14.00	2,081,210	No	4	P	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See footnote
No	4	C	Indirect	See footnote
No	4	P	Indirect	See footnote

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Preferred Stock	Disposition	2013-05-14	8,640,289	$0.00	1,152,039	$5.25
Common Stock	Series B Preferred Stock	Disposition	2013-05-14	5,040,221	$0.00	672,029	$7.73

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Indirect
0			No	4	C	Indirect

Footnotes

The Series A preferred stock and Series B preferred stock converted upon the closing of the Issuer's initial public offering at a conversion ratio of 1 share of common stock for every 7.5 shares of Series A Preferred Stock and Series B Preferred Stock, for no additional consideration.
Beneficial ownership consists of: (i) 257,142 shares of common stock held by Lilly Ventures Fund I, LLC ("Lilly Ventures"); and (ii) an aggregate of 1,824,068 shares of common stock issued upon conversion of shares of Series A preferred stock and Series B preferred stock held by Lilly Ventures. Mr. Torres is a non-managing member of Lilly Ventures and has shared voting and shared investment power over such shares, and may be deemed the indirect beneficial owner of such shares. Mr. Torres disclaims beneficial ownership over such shares, except to the extent of any pecuniary interest therein.